A popular antiparasitic drug called fenben for humans is showing promise in inhibiting the growth of cancer cells. It has caught the attention of researchers who study pancreatic cancer, as it may help boost positive results from traditional healing methods like radiation.
However, this is just preliminary research and needs to be confirmed by a clinical trial. So far, fenben for humans has only been used in two small clinical studies to treat parasites and was never tested on people with cancer. This drug is also not widely available in the US as it is mostly prescribed to veterinarians and sold under the brand name Panacur or Safe-Guard.
In-vitro studies have found that fenbendazole (FZ) has the potential to slow down cancer cell growth. But in-vitro studies rarely replicate when tested in animals or humans, so it is important to seek professional guidance on the most effective treatment options based on your unique health condition.
When fenbendazole was administered to human cancer cells, the anthelmintic effects were observed in the form of reduced uptake of the fluorescent glucose analogue 2-NBDG as well as decreased expression of GLUT transporters and key glycolytic enzymes. In addition, fenbendazole (FZ) caused mitochondrial translocation of p53 and disrupted microtubule dynamics.
While the anthelmintic drugs fenben and mebendazole are similar in some ways, fenbendazole is not approved for use as an anti-cancer medication and should not be taken without a doctor’s supervision. But despite the lack of scientific data, some individuals have chosen to self-administer this drug and report success in slowing their cancer progression.